Another therapeutic possibility is brentuximab vedotin, an anti-CD30 monoclonal antibody conjugated to the antimicrotubule cytotoxic agent monomethyl auristatin, which is an option in combination with ALK-inhibition in ALCL. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.